title: Endometrial thickness after menopause: effect of hormone replacement.
abstract: Ultrasound (US) images of the pelvis were evaluated in 112 asymptomatic postmenopausal women to investigate the normal range of endometrial thickness (double-layer measurement) and the effect of hormone replacement on these measurements. Twenty-one patients (19%) had endometrial thickness greater than 0.8 cm. One patient, with an endometrial thickness of 2.5 cm, had endometrial carcinoma. Consideration of the known actions of estrogen and progestogen on the endometrium led the authors to believe that the clinical significance of an endometrium measuring more than 0.8 cm depends on the patient's hormonal status. Among asymptomatic postmenopausal women with an endometrial thickness between 0.8 and 1.5 cm, those receiving unopposed estrogen or continuous estrogen and progestogen need to undergo dilatation and curettage (D&C) or biopsy and those receiving no hormones or receiving sequential estrogen and progestogen should be encouraged to undergo D&C or biopsy. If a patient in one of the latter two groups is unwilling to undergo an invasive procedure, then US examination at 3-month intervals is acceptable. Any patient with endometrial thickness of at least 1.5 cm should undergo histologic diagnosis, regardless of symptoms or hormone status.
authors.affiliation: Department of Radiology, University of California, San Diego 92103.
authors.forename: M C
authors.initials: MC
authors.lastname: Lin
authors.forename: B B
authors.initials: BB
authors.lastname: Gosink
authors.forename: S I
authors.initials: SI
authors.lastname: Wolf
authors.forename: M R
authors.initials: MR
authors.lastname: Feldesman
authors.forename: C A
authors.initials: CA
authors.lastname: Stuenkel
authors.forename: P S
authors.initials: PS
authors.lastname: Braly
authors.forename: D H
authors.initials: DH
authors.lastname: Pretorius
mesh_terms: D001706:Biopsy; D004107:Dilatation and Curettage; D004717:Endometrium / Q000000981:diagnostic imaging* / Q000473:pathology; D015914:Estrogen Replacement Therapy; D004967:Estrogens / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006965:Hyperplasia; D008525:Medroxyprogesterone / Q000031:analogs & derivatives / Q000627:therapeutic use; D017258:Medroxyprogesterone Acetate; D008593:Menopause; D008875:Middle Aged; D013997:Time Factors; D014463:Ultrasonography
chemical_list: D004967:Estrogens; D017258:Medroxyprogesterone Acetate; D008525:Medroxyprogesterone